Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.49 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377574 | 0.92 | ALOX5 (0.58) | CPA3ALOX5KDM4AKDM5AKDM4C | |
| SCHEMBL1374778 | 0.87 | CPA3 (0.58) | CPA3ALOX5FOLH1NAALAD2 | |
| SCHEMBL2368874 | 0.86 | CPA3 (0.54) | CPA3ALOX5KEAP1KDM4AKDM5A | |
| SCHEMBL2368738 | 0.81 | CPA3 (0.51) | CPA3ALOX5KEAP1KDM4AKDM5A | |
| SCHEMBL2368373 | 0.79 | CPA3 (0.55) | CPA3FOLH1NAALAD2 | |
| SCHEMBL31379023 | 0.79 | ALOX5 (0.56) | CPA3ALOX5KEAP1KDM4AKDM5A | |
| SCHEMBL7350860 | 0.78 | CPA3 (0.71) | CPA3KEAP1FFAR1FOLH1HDAC3 | |
| SCHEMBL1377642 | 0.78 | CPA3 (0.53) | CPA3FOLH1NAALAD2MAPK1 | |
| SCHEMBL31379020 | 0.77 | ALOX5 (0.61) | CPA3ALOX5KDM4AKDM5AKDM4C | |
| SCHEMBL2368499 | 0.75 | CPA3 (0.50) | CPA3FOLH1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973731-B1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2002-08-28 | — | — | EP | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| US-20010044459-A1 | Hydroxamic acid derivatives | JACKSON PAUL F (US) | 2001-11-22 | — | — | US | claimed |
| JP-2001519809-A | — | — | 2001-10-23 | — | — | JP | claimed |
| EP-0973731-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-26 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| WO-1998045256-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | claimed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-20010044459-A1 | Hydroxamic acid derivatives | JACKSON PAUL F (US) | 2001-11-22 | — | — | US | disclosed |
| US-6271245-B1 | INHIBITORS OF N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME FOR TREATING GLUTAMATE ABNORMALITY (EPILEPSY, STROKE, ALZHEIMER'S DISEASE, SCHIZOPHRENIA, PAIN, ISCHMIA, PARKINSON'S AND HUNTINGTON'S) AND PROSTATE CANCER | GUILFORD PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| EP-0973731-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998045256-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CPA3 525/4885ALOX5 4272/4885KEAP1 3598/4885 |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CPA3 525/4885ALOX5 4272/4885KEAP1 3598/4885 |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CPA3 525/4885ALOX5 4272/4885KEAP1 3598/4885 |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CPA3 525/4885ALOX5 4272/4885KEAP1 3598/4885 |
| US-20010044459-A1 | Hydroxamic acid derivatives | NAALAD2, DNPEP, NAAA | CPA3 469/4885ALOX5 2026/4885KEAP1 2675/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CPA3 525/4885ALOX5 4272/4885KEAP1 3598/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CPA3 525/4885ALOX5 4272/4885KEAP1 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.